कंपनी का अवलोकन
Xenetic Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to advancing immune-oncology technologies designed to treat various forms of cancer. The company's core operational focus involves utilizing its proprietary DNase technology to specifically target neutrophil extracellular traps, which play a critical role in facilitating cancer growth, metastasis, and progression while influencing the efficacy of immunotherapy and chemotherapy treatments. This entity functions within the broader Healthcare sector and is classified specifically under the Biotechnology industry, positioning it to leverage biological innovations for therapeutic development. As of the latest available data, the company holds a market capitalization of $6.99M and generates annual revenue of $2.98M, supported by a workforce of 2 employees. These financial dimensions indicate that Xenetic Biosciences is a micro-cap entity with a very small operational footprint, suggesting that the company is in an early-stage development phase where capital allocation is heavily weighted toward research and development rather than large-scale commercialization or extensive personnel deployment.
वित्तीय स्वास्थ्य
The company reported a total revenue of $2.98M over the trailing twelve months, yet simultaneously recorded a net income of $-2,680,860, highlighting a significant operational deficit where costs substantially exceeded earnings. Although the company reports an EBITDA figure as not applicable due to its loss-making status, the disparity between its $2.98M revenue and the $-2.68M net loss reveals a cost structure dominated by high research and development expenditures or other operating expenses that are not yet offset by commercial sales. The firm's free cash flow stands at $-1,377,405, indicating a continuous outflow of cash which limits immediate financial flexibility but is typical for pre-revenue biotechnology firms investing heavily in clinical trials or technology maturation. Xenetic Biosciences maintains a gross margin of 100.0%, suggesting that its product sales or licensing agreements do not incur direct cost of goods sold, a common characteristic of early-stage biotech revenue models. However, the operating margin is negative at -81.3% and the profit margin is even more depressed at -90.1%, reflecting substantial overhead burdens relative to the current revenue base. The balance sheet shows a cash position of $7.88M contrasted against zero total debt, resulting in a debt-to-equity ratio that is not applicable due to the absence of debt obligations. This combination of significant cash reserves and no leverage characterizes a conservative balance sheet structure, providing the company with a robust runway to fund operations without the pressure of interest payments. Furthermore, the current ratio is recorded at 8.32, which signifies an extremely strong short-term liquidity position, implying that the company possesses ample current assets to cover its current liabilities many times over. The return on equity is reported at -40.0% and the return on assets at -23.2%, metrics that reveal that management effectiveness in generating profit is currently constrained by the company's stage of development and its inability to yet convert equity and asset bases into positive shareholder returns.
मूल्यांकन आकलन
Xenetic Biosciences, Inc. presents a trailing P/E ratio that is not applicable due to negative earnings, while the forward P/E is listed as -4.62, implying that analysts or market participants expect earnings to remain negative or for the company to continue operating at a loss in the near future. The price-to-book ratio is 0.95, indicating that the market is valuing the company at roughly equal to its net book value, which suggests a lack of significant market premium over the accounting value of its assets. When utilizing alternative valuation metrics, the price-to-sales ratio stands at 2.35, and the EV/EBITDA is not applicable, suggesting that investors are pricing the stock primarily based on its revenue potential rather than earnings power or enterprise value multiples. The stock has exhibited a volatility range with a 52-week high of $13.93 and a 52-week low of $1.90, meaning the current trading price sits within a wide historical band that reflects the speculative nature of small-cap biotechnology equities. The beta value is 2.21, which indicates that the stock's price volatility is more than twice that of the broader market, signifying that price movements will be amplified relative to general market trends during periods of instability.
Growth & Income
The company achieved a revenue growth year-over-year of 18.1%, whereas the earnings growth is not applicable due to the company's consistent net losses, implying that revenue expansion is currently being outpaced by the fixed and variable costs required to sustain operations. Since the company does not distribute dividends, the dividend yield is not applicable and the payout ratio is 0.0%, indicating that the firm retains all its earnings to reinvest into its scientific pipeline and growth initiatives rather than providing income to shareholders. This reinvestment strategy is standard for biotechnology firms that prioritize capitalizing on research and development to achieve future profitability over providing immediate cash returns to investors. Overall, the growth and income profile of Xenetic Biosciences is defined by double-digit revenue expansion coupled with negative earnings and a complete absence of dividend distributions, reflecting a capital-intensive business model focused on long-term technological advancement rather than short-term financial returns.